395 related articles for article (PubMed ID: 31229163)
1. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.
Hunter BD; Chen YB; Jacobson CA
Hematol Oncol Clin North Am; 2019 Aug; 33(4):687-705. PubMed ID: 31229163
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.
Gauthier J; Maloney DG
Hematol Oncol Clin North Am; 2020 Oct; 34(5):957-970. PubMed ID: 32861289
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
4. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
Merryman RW; Houot R; Armand P; Jacobson C
Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
[TBL] [Abstract][Full Text] [Related]
5. Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.
Jain T; Sauter CS; Shah GL; Maloy MA; Chan J; Scordo M; Avecilla ST; Batlevi Y; Dahi PB; Batlevi CW; Lia Palomba M; Giralt SA; Perales MA
Leukemia; 2019 Oct; 33(10):2540-2544. PubMed ID: 31114023
[No Abstract] [Full Text] [Related]
6. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.
Ghobadi A
Curr Res Transl Med; 2018 May; 66(2):43-49. PubMed ID: 29655961
[TBL] [Abstract][Full Text] [Related]
7. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma.
Komanduri KV
J Clin Oncol; 2021 Feb; 39(5):476-486. PubMed ID: 33434079
[No Abstract] [Full Text] [Related]
9. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Levin A; Shah NN
Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Kallam A; Vose JM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
[TBL] [Abstract][Full Text] [Related]
11. Cellular Therapy in Follicular Lymphoma: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, and Chimeric Antigen Receptor T-cell Therapy.
Okosun J; Montoto S
Hematol Oncol Clin North Am; 2020 Aug; 34(4):701-714. PubMed ID: 32586575
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
Frey NV
Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
[TBL] [Abstract][Full Text] [Related]
13. CAR-T in B-Cell Lymphomas: The Past, Present, and Future.
Al-Juhaishi T; Ahmed S
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e261-e268. PubMed ID: 34782260
[TBL] [Abstract][Full Text] [Related]
14. CAR T cells: The future is already present.
Sánchez-Escamilla M; Yáñez San Segundo L; Urbano-Ispizua Á; Perales MÁ
Med Clin (Barc); 2019 Apr; 152(7):281-286. PubMed ID: 30392694
[No Abstract] [Full Text] [Related]
15. Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature.
Mercadal S; Mussetti A; Lee CJ; Arevalo C; Odstrcil SM; Peña E; Sureda A; Couriel DR
Ann Hematol; 2024 May; 103(5):1717-1727. PubMed ID: 38429536
[TBL] [Abstract][Full Text] [Related]
16. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma.
Lulla PD; Hill LC; Ramos CA; Heslop HE
Clin Adv Hematol Oncol; 2018 May; 16(5):375-386. PubMed ID: 29851933
[TBL] [Abstract][Full Text] [Related]
17. Posttransplant chimeric antigen receptor therapy.
Smith M; Zakrzewski J; James S; Sadelain M
Blood; 2018 Mar; 131(10):1045-1052. PubMed ID: 29358181
[TBL] [Abstract][Full Text] [Related]
18. Novel therapies for relapsed/refractory aggressive lymphomas.
Cohen JB
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):75-82. PubMed ID: 30504294
[TBL] [Abstract][Full Text] [Related]
19. Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma.
Li C; Zhang Y; Zhang C; Chen J; Lou X; Chen X; Kang L; Xu N; Li M; Tan J; Sun X; Zhou J; Yang Z; Zong X; Wang P; Xu T; Qu C; Huang H; Jin Z; Yu L; Wu D
JCI Insight; 2019 Jul; 5(17):. PubMed ID: 31335321
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
Ahmadi P; Ghandili S; Jakobs F; Konnopka C; Morgner-Miehlke A; Kröger N; Ayuk F
Bone Marrow Transplant; 2024 Apr; 59(4):572-574. PubMed ID: 38321270
[No Abstract] [Full Text] [Related]
[Next] [New Search]
